Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
6.13
+0.38 (6.52%)
Sep 28, 2026, 4:00 PM EDT - Market closed
Alvotech Revenue
Alvotech had revenue of $105.77M in the quarter ending June 30, 2026, a decrease of -38.94%. This brings the company's revenue in the last twelve months to $491.95M, down -12.17% year-over-year. In the year 2025, Alvotech had annual revenue of $586.32M with 19.74% growth.
Revenue (ttm)
$491.95M
Revenue Growth
-12.17%
P/S Ratio
4.41
Revenue / Employee
$386,715
Employees
1,279
Market Cap
2.19B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 586.32M | 96.64M | 19.74% |
| Dec 31, 2024 | 489.68M | 398.25M | 435.56% |
| Dec 31, 2023 | 91.43M | 8.41M | 10.12% |
| Dec 31, 2022 | 83.03M | 46.26M | 125.79% |
| Dec 31, 2021 | 36.77M | -29.84M | -44.80% |
| Dec 31, 2020 | 66.62M | 34.70M | 108.71% |
| Dec 31, 2019 | 31.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.85B |
| Perrigo Company | 4.14B |
| Phibro Animal Health | 1.52B |
| Trulieve Cannabis | 1.14B |
| Prestige Consumer Healthcare | 1.10B |
| ANI Pharmaceuticals | 978.38M |
| BioCryst Pharmaceuticals | 940.61M |
| Supernus Pharmaceuticals | 830.44M |
ALVO News
- 12 days ago - Alvotech upgraded to Overweight from Underweight at Barclays - TheFly
- 13 days ago - Alvotech Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 4 weeks ago - Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations - GlobeNewsWire
- 4 weeks ago - Alvotech to present at upcoming investor conferences in September - GlobeNewsWire
- 5 weeks ago - Alvotech initiated with a Buy at BofA - TheFly
- 5 weeks ago - Alvotech enters licensing, commercialization agreement with Lotus Pharmaceutical - TheFly
- 5 weeks ago - Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets - GlobeNewsWire
- 5 weeks ago - Alvotech Earnings Call Transcript: Q2 2026 - Transcripts